ducovest

XVIPF:OTO-Xvivo Perfusion Ab Ord (USD)

COMMON STOCK | Medical Devices | OTC Pink

Last Closing

USD 49.4

Change

-1.76 (-3.44)%

Market Cap

USD 0.22B

Volume

300.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Xvivo Perfusion AB is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation.

Company Website : http://www.xvivoperfusion.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SEMHF Siemens Healthineers AG

N/A

 USD 64.87B
SMMNY Siemens Healthineers AG ADR

N/A

 USD 63.28B
RYLPF Koninklijke Philips N.V

N/A

 USD 28.54B
SONVF Sonova Holding AG

N/A

 USD 20.85B
SNNUF Smith & Nephew plc

N/A

 USD 13.71B
WILLF Demant A/S

N/A

 USD 9.10B
GNGBF Getinge AB

N/A

 USD 5.77B
AMBBY Ambu A/S

N/A

 USD 4.99B
AMBFF Ambu A/S

N/A

 USD 4.99B
GGNDF GN Store Nord A/S

N/A

 USD 3.66B

ETFs Containing XVIPF

RUBY:CA RBC U.S. Banks Yield Inde.. 7.27 % 0.33 %

N/A

 CAD 0.01B
RUBY-U:CA RBC U.S. Banks Yield Inde.. 7.27 % 0.00 %

N/A

 N/A
ZWK:CA BMO Covered Call US Banks.. 6.67 % 0.00 %

N/A

 CAD 0.34B
ZBK:CA BMO Equal Weight US Banks.. 6.10 % 0.37 %

N/A

 CAD 0.68B
IUS2:F iShares S&P U.S. Banks UC.. 4.18 % 0.00 %

N/A

 N/A
BNKS:LSE iShares S&P U.S. Banks 4.17 % 0.00 %

N/A

 N/A
FBU:CA 2.78 % 0.84 %

N/A

 N/A
KRS 2.30 % 0.95 %

N/A

 N/A
KRU 2.30 % 0.95 %

N/A

 N/A
MVIN 2.28 % 0.55 %

N/A

 N/A
KRE SPDR® S&P Regional Banki.. 2.23 % 0.35 %

N/A

 N/A
SDOG ALPS Sector Dividend Dogs.. 2.18 % 0.40 %

N/A

 USD 1.21B
IXG iShares Global Financials.. 0.00 % 0.46 %

N/A

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 116.67% 92% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 116.67% 92% A 94% A
Trailing 12 Months  
Capital Gain 86.91% 91% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 86.91% 91% A- 91% A-
Trailing 5 Years  
Capital Gain 188.89% 91% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 188.89% 89% A- 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 37.69% N/A N/A 73% C
Dividend Return 37.69% N/A N/A 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 77.86% N/A N/A 38% F
Risk Adjusted Return 48.40% N/A N/A 84% B
Market Capitalization 0.22B 87% B+ 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.